Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma

American Journal of Clinical Pathology

Volumn 128, Issue 5, 2007, Pages 808-816

  Zhang, Megan Q ^a,e   Lin, Fan ^b   Hui, Pei ^c   Chen, Zong Ming E ^a   Ritter, Jon H ^a   Wang, Hanlin L ^a,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adenocarcinoma; CDX2; Colorectal; Mucin; Small intestine; Small intestinal mucin antigen; Villin

Indexed keywords

ANTIBODY; ANTIGEN; BIOLOGICAL MARKER; MUCIN; MUCIN 2; MUCIN 3; MUCIN 5AC; SMALL INTESTINAL MUCIN ANTIGEN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VILLIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MUCINS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 36248970126     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/JAF3KVGJHQCJ1QF9     Document Type: Article

References (33)

1. Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol. 1996;25:722-728.
2. Howe JR, Karnell LH, Menck HR, et al. The American College of Surgeons Commission on Cancer and the American Cancer Society: adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer. 1999;86:2693-2706.
3. Sellner F. Investigations on the significance of the adenomacarcinoma sequence in the small bowel. Cancer. 1990;66:702-715.
4. Neugut AI, Marvin MR, Rella VA, et al. An overview of adenocarcinoma of the small intestine. Oncology. 1997;11:529-536.
5. Delaunoit T, Neczyporenko F, Limburg PJ, et al. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol. 2005;100:703-710.
6. Chen ZM, Wang HL. Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. Am J Surg Pathol. 2004;28:1352-1359.
7. Chen ZM, Ritter JR, Wang HL. Differential expression of α-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol. 2005;29:890-896.
8. Zhang MQ, Chen ZM, Wang HL. Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol. 2006;19:573-580.
9. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77-99.
10. Yamasaki H, Ikeda S, Okajima M, et al. Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors. Int J Oncol. 2004;24:107-113.
11. Paulsen FP, Varoga D, Paulsen AR, et al. Prognostic value of mucins in the classification of ampullary carcinomas. Hum Pathol. 2006;37:160-167.
12. Rakha E, Boyce R, El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005;18:1295-1304.
13. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-175.
14. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45-60.
15. Corfield AP, Myerscough N, Longman R, et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut. 2000;47:589-594.
16. Lee MJ, Lee HS, Kim WH, et al. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16:403-410.
17. Gürbüz Y, Klöppel G. Differentiation pathways in duodenal and ampullary carcinomas: a comparative study on mucin and trefoil peptide expression, including gastric and colon carcinomas. Virchows Arch. 2004;444:536-541.
18. Hertzog PJ, Pilbrow SJ, Linnane AW, et al. Aberrant expression of intestinal mucin antigens associated with colorectal carcinoma defined by a panel of monoclonal antibodies. Br J Cancer. 1991;64:799-808.
19. Hertzog PJ, Robinson HC, Ma J, et al. Oncofetal expression of the human intestinal mucin glycoprotein antigens in gastrointestinal epithelium defined by monoclonal antibodies. Int J Cancer. 1991;48:355-363.
20. Pilbrow SJ, Hertzog PJ, Linnane AW, et al. The adenomacarcinoma sequence in the colorectum: early appearance of a hierarchy of small intestinal mucin antigen (SIMA) epitopes and correlation with malignant potential. Br J Cancer. 1992;66:748-757.
21. Athman R, Louvard D, Robine S. The epithelial cell cytoskeleton and intracellular trafficking, III: how is villin involved in the actin cytoskeleton dynamics in intestinal cells? Am J Physiol Gastrointest Liver Physiol. 2002;283:G496-G502.
22. Bacchi CE, Gown AM. Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffin-embedded tissue. Lab Invest. 1991;64:418-424.
23. Moll R, Robine S, Dudouet B, et al. Villin: a cytoskeletal protein and a differentiation marker expressed in some human adenocarcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;54:155-169.
24. West AB, Isaac CA, Carboni JM, et al. Localization of villin, a cytoskeletal protein specific to microvilli, in human ileum and colon and in colonic neoplasms. Gastroenterology. 1988;94:343-352.
25. Werling R, Yaziji H, Bacchi C, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
26. Nishizuka S, Chen ST, Gwadry FG, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 2003;63:5243-5250.
27. Suh N, Yang XJ, Tretiakova MS, et al. Value of CDX2, villin, and α-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol. 2005;18:1217-1222.
28. Bismar TA, Humphrey PA, Grignon DJ, et al. Expression of β-catenin in prostatic adenocarcinomas: a comparison with colorectal adenocarcinomas. Am J Clin Pathol. 2004;121:557-563.
29. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004;17:1392-1399.
30. Li MK, Folpe AL. CDX-2, a new marker for adenocarcinoma of gastrointestinal origin. Adv Anat Pathol. 2004;11:101-105.
31. De Lott LB, Morrison C, Suster S, et al. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med. 2005;129:1100-1105.
32. Groisman GM, Bernheim J, Halpern M, et al. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum. Arch Pathol Lab Med. 2005;129:920-923.
33. Rozek LS, Lipkin SM, Fearon ER, et al. CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res. 2005;65:5488-5492.